The University of Southampton
University of Southampton Institutional Repository

A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial

A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial
A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial

Background: Antidepressants are used both for treating acute episodes and for prophylaxis to prevent future episodes of depression, also called maintenance treatment. This article describes the protocol for a randomised controlled trial (ANTLER: ANTidepressants to prevent reLapse in dEpRession) to investigate the clinical effectiveness and cost-effectiveness in UK primary care of continuing on long-term maintenance antidepressants compared with a placebo in preventing relapse of depression in those who have taken antidepressants for more than 9 months and who are currently well enough to consider stopping maintenance treatment. Methods/design: The ANTLER trial is an individually randomised, double-blind, placebo-controlled trial in which participants are randomised to remain on active medication or to take an identical placebo after a tapering period of 2 months. Eligible participants are those who: are between the ages of 18 and 74 years; have had at least two episodes of depression; and have been taking antidepressants for 9 months or more and are currently taking citalopram 20 mg, sertraline 100 mg, fluoxetine 20 mg or mirtazapine 30 mg but are well enough to consider stopping their medication. The participants will be followed up at 6, 12, 26, 39 and 52 weeks. The primary outcome will be the time in weeks to the beginning of the first episode of depression after randomisation. This will be measured using a retrospective version of the Clinical Interview Schedule - Revised administered at 12, 26, 39 and 52 weeks. Secondary outcomes will include depressive and anxiety symptoms, adverse effects, withdrawal symptoms, emotional processing tasks, quality of life and the resources and costs used. We will also perform a cost-effectiveness analysis based on results of the trial. Discussion: The ANTLER trial findings will inform primary care prescribing practice by providing a valid and generalisable estimate of the clinical effectiveness and cost-effectiveness of long-term maintenance treatment with antidepressants in UK primary care. Trial registration: Controlled Trials ISRCTN Registry, ISRCTN15969819. Registered on 21 September 2015.

Antidepressants, Citalopram, Depression, Fluoxetine, Mirtazapine, Primary care, Selective serotonin reuptake inhibitors, Sertraline
1745-6215
1-13
Duffy, Larisa
68ab154c-9825-44ad-8385-b3dcadf30651
Bacon, Faye
2ad97865-e909-4bff-8f55-be8f2b8d4e6b
Clarke, Caroline S.
ecc070e4-31d9-42f4-8104-77be07561b58
Donkor, Yvonne
e01e4992-1de4-4ff2-99bd-3ad4698c3417
Freemantle, Nick
8182a4ad-e20e-4aea-b5f7-62b170845d1e
Gilbody, Simon
6d135882-a8df-444c-85aa-980dddef45a5
Hunter, Rachael
155068d4-d49a-4180-8eb0-0c549aa7f95c
Kendrick, Tony
c697a72c-c698-469d-8ac2-f00df40583e5
Kessler, David
3659e526-e667-46cb-bd9c-02bce7d58d41
King, Michael
cf8c59d9-802d-45b8-8413-be0d41446c0d
Lanham, Paul
2bcf9c17-6c36-47a1-8714-3bc984ae4406
Lewis, Gemma
736f9361-ca4d-4347-bc75-18d21fda5052
Mangin, Dee
911e4c3d-2444-4fb1-bd08-5fb1b54ce359
Marston, Louise
258cc87f-2cf7-49de-9498-fc659a5ffde7
Moore, Michael
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Nazareth, Irwin
630042a9-f574-448d-85fa-d2ac3a6807b5
Wiles, Nicola
fcec2769-de78-4b86-b9c1-eab754a02837
Lewis, Glyn
11aed8f6-3905-455e-8e89-34147a5e5d26
Duffy, Larisa
68ab154c-9825-44ad-8385-b3dcadf30651
Bacon, Faye
2ad97865-e909-4bff-8f55-be8f2b8d4e6b
Clarke, Caroline S.
ecc070e4-31d9-42f4-8104-77be07561b58
Donkor, Yvonne
e01e4992-1de4-4ff2-99bd-3ad4698c3417
Freemantle, Nick
8182a4ad-e20e-4aea-b5f7-62b170845d1e
Gilbody, Simon
6d135882-a8df-444c-85aa-980dddef45a5
Hunter, Rachael
155068d4-d49a-4180-8eb0-0c549aa7f95c
Kendrick, Tony
c697a72c-c698-469d-8ac2-f00df40583e5
Kessler, David
3659e526-e667-46cb-bd9c-02bce7d58d41
King, Michael
cf8c59d9-802d-45b8-8413-be0d41446c0d
Lanham, Paul
2bcf9c17-6c36-47a1-8714-3bc984ae4406
Lewis, Gemma
736f9361-ca4d-4347-bc75-18d21fda5052
Mangin, Dee
911e4c3d-2444-4fb1-bd08-5fb1b54ce359
Marston, Louise
258cc87f-2cf7-49de-9498-fc659a5ffde7
Moore, Michael
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Nazareth, Irwin
630042a9-f574-448d-85fa-d2ac3a6807b5
Wiles, Nicola
fcec2769-de78-4b86-b9c1-eab754a02837
Lewis, Glyn
11aed8f6-3905-455e-8e89-34147a5e5d26

Duffy, Larisa, Bacon, Faye, Clarke, Caroline S., Donkor, Yvonne, Freemantle, Nick, Gilbody, Simon, Hunter, Rachael, Kendrick, Tony, Kessler, David, King, Michael, Lanham, Paul, Lewis, Gemma, Mangin, Dee, Marston, Louise, Moore, Michael, Nazareth, Irwin, Wiles, Nicola and Lewis, Glyn (2019) A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial. Trials, 20 (1), 1-13, [319]. (doi:10.1186/s13063-019-3390-8).

Record type: Article

Abstract

Background: Antidepressants are used both for treating acute episodes and for prophylaxis to prevent future episodes of depression, also called maintenance treatment. This article describes the protocol for a randomised controlled trial (ANTLER: ANTidepressants to prevent reLapse in dEpRession) to investigate the clinical effectiveness and cost-effectiveness in UK primary care of continuing on long-term maintenance antidepressants compared with a placebo in preventing relapse of depression in those who have taken antidepressants for more than 9 months and who are currently well enough to consider stopping maintenance treatment. Methods/design: The ANTLER trial is an individually randomised, double-blind, placebo-controlled trial in which participants are randomised to remain on active medication or to take an identical placebo after a tapering period of 2 months. Eligible participants are those who: are between the ages of 18 and 74 years; have had at least two episodes of depression; and have been taking antidepressants for 9 months or more and are currently taking citalopram 20 mg, sertraline 100 mg, fluoxetine 20 mg or mirtazapine 30 mg but are well enough to consider stopping their medication. The participants will be followed up at 6, 12, 26, 39 and 52 weeks. The primary outcome will be the time in weeks to the beginning of the first episode of depression after randomisation. This will be measured using a retrospective version of the Clinical Interview Schedule - Revised administered at 12, 26, 39 and 52 weeks. Secondary outcomes will include depressive and anxiety symptoms, adverse effects, withdrawal symptoms, emotional processing tasks, quality of life and the resources and costs used. We will also perform a cost-effectiveness analysis based on results of the trial. Discussion: The ANTLER trial findings will inform primary care prescribing practice by providing a valid and generalisable estimate of the clinical effectiveness and cost-effectiveness of long-term maintenance treatment with antidepressants in UK primary care. Trial registration: Controlled Trials ISRCTN Registry, ISRCTN15969819. Registered on 21 September 2015.

Text
s13063-019-3390-8 - Version of Record
Available under License Creative Commons Attribution.
Download (1MB)

More information

Accepted/In Press date: 2 May 2019
Published date: 3 June 2019
Keywords: Antidepressants, Citalopram, Depression, Fluoxetine, Mirtazapine, Primary care, Selective serotonin reuptake inhibitors, Sertraline

Identifiers

Local EPrints ID: 431983
URI: http://eprints.soton.ac.uk/id/eprint/431983
ISSN: 1745-6215
PURE UUID: 3baff159-275b-48df-9922-3a3589437b7a
ORCID for Tony Kendrick: ORCID iD orcid.org/0000-0003-1618-9381
ORCID for Michael Moore: ORCID iD orcid.org/0000-0002-5127-4509

Catalogue record

Date deposited: 26 Jun 2019 16:30
Last modified: 18 Feb 2021 17:03

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×